



Cardiac Biomarkers: *Technologies and Global Markets*

July 2018

Paul Taylor

Report Code: BIO128C

Table of Contents

Chapter 1: Introduction	2
Scope of the Report	3
Methodology and Information Sources	4
Primary Data and Information Gathering	4
Secondary Data and Information Gathering	5
Market Share Analysis and Market Forecast Prediction	5
Geographic Breakdown.....	6
Analyst’s Credentials.....	9
Related BCC Research Reports.....	9
Chapter 2: Summary and Highlights	11
Chapter 3: Cardiovascular Disease and Burden of Cardiovascular Disease	16
Overview of Cardiovascular Disease	16
Coronary Artery Disease.....	16
Atherosclerosis	16
Angina (Angina Pectoris)	18
Acute Myocardial Infarction.....	20
Disease Management	21
Medical Management	21
Lifestyle Changes.....	21
Diet Modification.....	21
Smoking Cessation.....	22
Pharmaceuticals	22
Anticoagulants and Antiplatelet Drugs	23
Lipid-Lowering Drugs.....	24
Anti-Hypertensive Drugs	26
Nitroglycerin Preparations	27
Surgical Intervention	27
The Global Burden of Cardiovascular Disease	29
Global Burden of Cardiovascular Disease, 2015.....	29
2030 Global Burden of Cardiovascular Disease	38
The Global Economic Burden of Cardiovascular Disease	43
Chapter 4: Introduction to Cardiac Biomarkers	48
Types of Biomarkers.....	49
Antecedent Biomarker Tests.....	49
Screening Biomarker Tests	49
Diagnostic Biomarker Tests	50
Staging Biomarkers.....	50
Prognostic Biomarker Tests.....	50
Role of Biomarkers in the Prevention, Assessment and Management of Heart Failure	50
Myocardial Stress/Injury	51
Neurohormonal Activation.....	58
Remodeling.....	59
Comorbidities	64
Other Biomarkers of Cardiac Activity	65
Their Role of Biomarkers in Heart Failure Clinical Trials	69

Biomarker Discovery and Validation.....	70
Biomarker Candidate Screening.....	70
Biomarker Candidate Validation.....	71
Omic Technologies for Biomarker Discovery.....	71
Genomics.....	71
Proteomics.....	72
Metabolomics.....	75
Lipidomics.....	75
Considerations When Developing a Cardiac Biomarker.....	76
Defining Abnormal Biomarker Values.....	77
Reference Limits.....	79
Discrimination Limits.....	80
Threshold Defining Risk.....	80
Receiver Operating Characteristic Curve Analysis of Biomarker Accuracy.....	82
Chapter 5: Review of Key Individual Cardiac Biomarkers.....	84
Gold Standard of Cardiac Biomarkers.....	84
Troponin Complex.....	86
Troponin C.....	86
Troponin T.....	87
Troponin I.....	87
Troponin as the Preferred Biomarker.....	89
High Sensitivity Troponin Assays.....	89
Emergence of Point-of-Care Troponin Testing.....	93
Pro-BNP and/or NT-proBNP.....	100
Creatine Kinase Test.....	105
Myoglobin (Mb).....	106
C-Reactive Protein.....	109
Other Key Cardiac Biomarkers.....	110
Copeptin.....	110
D-dimer.....	111
Galectin-3.....	112
Fatty Acid Binding Proteins.....	113
ST2.....	113
Emerging Cardiac Biomarkers.....	114
Choline.....	114
Ischemia-Modified Albumin.....	115
Myeloperoxidase.....	116
S100-beta.....	116
Recent Technological Advances and Key Developments in Cardiac Biomarker Measurement.....	117
Chapter 6: Global Cardiac Biomarker Market Analysis.....	121
Introduction.....	121
Global Cardiac Biomarker Market by Cardiac Biomarker Type.....	121
North American Cardiac Biomarker Market Analysis.....	126
Selected Drivers of the North American Cardiac Biomarker Market.....	129
North American Cardiac Biomarker Market, by Country.....	133
European Cardiac Biomarker Market Analysis.....	136
Selected Drivers of the European Cardiac Biomarker Market.....	139
Selected Restraints of the European Cardiac Biomarker Market.....	140
European Cardiac Biomarker Market, by Country.....	142

Asia-Pacific Cardiac Biomarker Market Analysis.....	151
Selected Drivers of the Asia-Pacific Cardiac Biomarker Market.....	154
Selected Restraints of the Asia-Pacific Cardiac Biomarker Market.....	156
Asia-Pacific Cardiac Biomarker Market by Country	159
Central and Latin American Cardiac Biomarker Market Analysis	165
Selected Drivers of the Central and Latin American Cardiac Biomarker Market.....	167
Selected Restraints of the Central and Latin American Cardiac Biomarker Market	169
Central and Latin American Cardiac Biomarker Market by Country.....	172
Middle East and African Cardiac Biomarker Market Analysis.....	179
Selected Drivers of the Middle East and African Cardiac Biomarker Market	181
Selected Restraints of the Middle East and African Cardiac Biomarker Market.....	182
Middle East and African Cardiac Biomarker Market by Region	183
Cardiac Biomarker Market Shares by Geographic Region	186
Global Market Share Analysis.....	186

Chapter 7: Regulatory and Legislative Requirements for Cardiac Biomarkers.... 193

North America.....	193
United States	193
Recent Developments	203
Canada.....	205
Europe.....	206
(General) Medical Device Directive, MDD (93/42/EEC)	206
Active Implantable Medical Device Directive, AIMDD (90/383/EEC).....	207
In Vitro Diagnostic Medical Device Directive, IVDMD (98/79/EC).....	208
Proposed Changes to the Medical Device Directive, MDD (93/42/EEC).....	208
Notified Bodies	210
German Reimbursement Structure and Schedules for Diagnostic Procedures	210
French Reimbursement Structure and Schedules for Diagnostic Procedures	212
Italian Reimbursement Structure and Schedules for Diagnostic Procedures	217
Japan	221
Marketing Authorization System	222
China	223
Overview of the Healthcare System.....	224
Healthcare Reforms.....	225
Healthcare Institutions.....	225
India	229
Overview of the Healthcare System.....	229
Hospital Resources	232
Population Statistics	233
South Korea.....	234
Brazil.....	235
Background.....	235
Regulatory and Legislative Requirements.....	237
Market Entry and Reimbursement of Medical Devices	237
Argentina.....	239
Background.....	239
Mexico.....	242
Legislation and Regulations Governing Medical Devices in Mexico	242
Health Insurance Structure	243

Chapter 8: Patent Review and New Developments for Cardiac Biomarkers..... 246

Introduction	246
Cardiac Biomarker Patents by Region and Country.....	249
Chapter 9: Company Profiles	257
Appendix A: Company Addresses and Contact Details	295
Company Addresses and Contact Details	295
Appendix B: Government Regulatory Agencies and Professional Organizations	303
Government Regulatory Agencies and Professional Organizations	303
Appendix C: Commonly Used Acronyms Associated with Cardiac Biomarkers...	306
About BCC Research.....	312
About BCC Research.....	313
BCC Library Access	313
BCC Custom Research	313

List of Tables

Summary Table A Global Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions)	11
Summary Table B Global Cardiac Biomarker Market Share, by Region, 2017 (%)	14
Table 1 Standard Angina Pectoris Classification	19
Table 2 Top 20 Leading Causes of Death, 2015	30
Table 3 Estimated Deaths Due to Noncommunicable Diseases, by Sex and Disease, 2015	31
Table 4 Estimated Deaths Due to Cardiovascular Disease, by Sex and Disease, 2015	32
Table 5 Global Health Estimates, by Sex and WHO Region, 2015	33
Table 6 Estimated Deaths Due to Cardiovascular Disease, by Sex and Disease, 2030 (No. of Deaths).....	39
Table 7 Estimated Deaths Due to Cardiovascular Disease, by Sex and WHO Region, 2030 (No. of Deaths)	39
Table 8 Economic Burden of NCDs in India, 2012–2030 (\$ Trillions).....	45
Table 9 Summary of Heart Failure Biomarkers	51
Table 10 Cardiac Biomarkers of Myocyte Stretch.....	52
Table 11 Cardiac Biomarkers of Myocyte Injury	55
Table 12 Cardiac Biomarkers of Oxidative Stress	57
Table 13 Cardiac Biomarkers of Neurohormonal Activation	59
Table 14 Prognostic and Diagnostic Values and Analytical Performance of Inflammatory Markers in Coronary Artery Disease	61
Table 15 Cardiac Biomarkers of Inflammation and Atherogenesis	62
Table 16 Cardiac Biomarkers of Renal Dysfunction	64
Table 17 Soluble Cell Adhesion Molecules	66
Table 18 Cardiac Biomarkers of Thrombosis	66
Table 19 Cardiac Biomarkers of Metabolic/Lipid Dysregulation	67
Table 20 Cardiac Biomarkers of Brain Damage.....	68
Table 21 Techniques Available for Biomarker Development	74
Table 22 Desirable Features of Cardiac Biomarkers	77
Table 23 Common Cardiac Biomarkers.....	84
Table 24 Contemporary Cardiac Troponin I and T Assay Analytical Characteristics as Designated by the Manufacturer	94
Table 25 High Sensitivity* Cardiac Troponin I and T Assay Analytical Characteristics Designated by Manufacturer	96
Table 26 Point-of-Care Cardiac Troponin I and T Assay Analytical Characteristics Designated by Manufacturer	98
Table 27 BNP, NT-proBNP and MR-proANP Assays: Analytical Characteristics Designated by Manufacturer	102
Table 28 Profile of Biomarker Myoglobin	107
Table 29 Profile of Biomarker ST2	115
Table 30 Global Cardiac Biomarker Market, Through 2022 (\$ Millions)	121
Table 31 Global Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions)	122
Table 32 Global Cardiac Biomarker Market Share, by Biomarker Type, 2017 (%)	123
Table 33 Global Cardiac Biomarker Market Share, by Region, 2017 (%)	125
Table 34 Global Cardiac Biomarker Market, by Region, 2017 (\$ Millions)	126
Table 35 Global Cardiac Biomarker Market, by Instrument Category, Through 2022 (\$ Millions)	126
Table 36 North American Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions)..	127
Table 37 North American Cardiac Biomarker Market, by Instrument Category, Through 2022 (\$ Millions)	128
Table 38 Projections of Crude CVD Prevalence in the United States, 2010–2030 (%)	129

Table 39 North American Cardiac Biomarker Market Share, by Country, 2017 (%).....	133
Table 40 United States Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions).....	134
Table 41 Canadian Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions)	136
Table 42 European Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions).....	137
Table 43 European Cardiac Biomarker Market, by Instrument Category, Through 2022 (\$ Millions)	138
Table 44 European Cardiac Biomarker Market Share, by Country, 2017 (%).....	142
Table 45 French Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions)	144
Table 46 German Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions)	145
Table 47 Italian Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions)	146
Table 48 Spanish Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions)	147
Table 49 United Kingdom Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions) ..	148
Table 50 Benelux Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions).....	149
Table 51 Scandinavian Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions)	150
Table 52 Rest of Europe Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions).....	151
Table 53 Asia-Pacific Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions)	152
Table 54 Asia-Pacific Cardiac Biomarker Market, by Instrument Category, Through 2022 (\$ Millions) ..	153
Table 55 Asia-Pacific Cardiac Biomarker Market Share, by Country, 2017 (%)	159
Table 56 Japanese Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions).....	160
Table 57 Chinese Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions).....	161
Table 58 Indian Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions)	162
Table 59 South Korean Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions).....	163
Table 60 Rest of Asia-Pacific Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions)	164
.....	
Table 61 Central and Latin American Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$	165
Millions)	
Table 62 Central and Latin American Cardiac Biomarker Market, by Instrument Category, Through 2022	166
(\$ Millions)	
Table 63 Central and Latin American Cardiac Biomarker Market Share, by Country, 2017 (%)	172
Table 64 Argentinian Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions).....	174
Table 65 Brazilian Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions).....	175
Table 66 Chilean Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions)	176
Table 67 Mexican Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions).....	177
Table 68 Rest of Central and Latin American Cardiac Biomarker Market, by Biomarker Type, Through	178
2022 (\$ Millions)	
Table 69 Middle East and African Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$	179
Millions)	
Table 70 Middle East and African Cardiac Biomarker Market, by Instrument Category, Through 2022 (\$	180
Millions)	
Table 71 Middle East and African Cardiac Biomarker Market Share, by Region, 2017 (%).....	183
Table 72 Middle Eastern Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions)	184
Table 73 African Cardiac Biomarker Market, by Biomarker Type, Through 2022 (\$ Millions).....	185
Table 74 Global Cardiac Biomarker Market Share, by Company, 2017 (%).....	186
Table 75 North American Cardiac Biomarker Market Share, by Company, 2017 (%)	187
Table 76 European Cardiac Biomarker Market Share, by Company, 2017 (%)	188
Table 77 Asia-Pacific Cardiac Biomarker Market Share, by Company, 2017 (%).....	189
Table 78 Latin and Central American Cardiac Biomarker Market Share, by Company, 2017 (%)	190
Table 79 Middle East and African Cardiac Biomarker Market Share, by Company, 2017 (%).....	191
Table 80 ICD-9 and ICD 10 CM Diagnosis Codes Commonly Used to Report Cardiac Conditions	202
Table 81 Clinical Diagnostic Laboratory Fee Schedule, 2018 (\$)	204
Table 82 Comparison of Pharmaceutical Affair Law and Japanese Medical Device Nomenclature and	221
Related Codes with the EU MDD	

Table 83 Number of Healthcare Institutions According to Ownership in China, 2010.....	226
Table 84 Total Number of Hospitals by Ranking in China, 2010.....	227
Table 85 Overview of Healthcare in India.....	230
Table 86 Recent Canadian Patent Publications Relating to Cardiac Biomarkers.....	249
Table 87 Recent Chinese Patent Publications Relating to Cardiac Biomarkers.....	249
Table 88 Recent European Patent Publications Relating to Cardiac Biomarkers.....	250
Table 89 Recent Eastern European Patent Publications Relating to Cardiac Biomarkers.....	250
Table 90 Recent U.S. Patent Publications Relating to Cardiac Biomarkers.....	251
Table 91 Recent Asia-Pacific Patent Publications Relating to Cardiac Biomarkers.....	253
Table 92 Recent Global Patent Publications Relating to Cardiac Biomarkers.....	254
Table 93 Abbott Laboratories' Revenue, by Business Segment, 2014-2016 (\$ Millions).....	258
Table 94 Danaher's Revenue, by Business Segment, 2014-2016 (\$ Millions).....	263
Table 95 BioMérieux S.A.'s Sales, by Application, 2015 to 2016 (\$ Millions).....	267
Table 96 Bio-Rad Laboratories Inc.'s Revenue, by Business Segment, 2014-2016 (\$ Millions).....	269
Table 97 Roche Group's Revenue, by Business Segment, 2014-2016 (\$ Millions).....	283
Table 98 Roche Group's Revenue, by Diagnostic Segment, 2014-2016 (\$ Millions).....	284
Table 99 Siemens AG Cardiovascular Assay Menu.....	286
Table 100 Thermo Fisher Scientific's Revenue, by Business Segment, 2014-2016 (\$ Millions).....	290
Table 101 Thermo Fisher Scientific's Results of Operations, by Region, 2014-2016 (\$ Millions).....	290
Table 102 Company Addresses and Contact Details.....	295
Table 103 Government Regulatory Agencies and Professional Organizations Associated with Cardiac Biomarkers.....	303
Table 104 Commonly Used Acronyms Associated with Cardiac Biomarkers.....	306

List of Figures

Summary Figure A Global Cardiac Biomarker Market Share, by Biomarker Type, 2017 (%).....	12
Summary Figure B Global Cardiac Biomarker Market Share, by Region, 2017 (%)	14
Figure 1 Global Distribution of Male Deaths Caused by Cardiovascular Disease, by Age, 2015 (No. of Deaths).....	35
Figure 2 Global Distribution of Male Deaths Caused, by Cardiovascular Disease, 2015 (%).....	36
Figure 3 Global Distribution of Female Deaths Caused by Cardiovascular Disease, by Age, 2015 (No. of Deaths).....	37
Figure 4 Global Distribution of Female Deaths Caused, by Cardiovascular Disease, 2015 (%)	38
Figure 5 Global Distribution of Male Deaths Caused by Cardiovascular Disease, by Age, 2030 (No. of Deaths).....	40
Figure 6 Global Distribution of Male Deaths Caused, by Cardiovascular Disease, 2030 (%).....	41
Figure 7 Global Distribution of Female Deaths Caused, by Cardiovascular Disease, by Age, 2030 (No. of Deaths).....	42
Figure 8 Global Distribution of Female Deaths Caused, by Cardiovascular Disease, 2030 (%)	43
Figure 9 Projected Total Costs of Cardiovascular Disease in The United States, 2015–2030.....	44
(\$ Billions).....	44
Figure 10 Classes of Biomarkers Contributing to the HF Biomarker Profile	53
Figure 11 Possible Roles of C-Reactive Protein in the Pathogenesis of Metabolic Syndrome and Cardiovascular Disorders	61
Figure 12 Biomarker Use in Heart Failure Trials (%)	70
Figure 13 Approaches to Defining Abnormal Biomarker Values	81
Figure 14 Receiver Operating Characteristic Curve in Different Cardiac Biomarkers	82
Figure 15 Interpreting Elevated Levels of Cardiac Troponin.....	90
Figure 16 Comparison of 19 Cardiac Troponin Assays.....	91
Figure 17 Schematic Diagram of the Synthesis of NT-proBNP and BNP from the Pre-proBNP Protein by Cardiomyocytes	100
Figure 18 Interpretation of NT-proBNP Values as a Predictor of Heart Failure.....	101
Figure 19 Global Cardiac Biomarker Market Share, by Biomarker Type, 2017 (%)	124
Figure 20 Global Cardiac Biomarker Market Share, by Region, 2017 (%).....	125
Figure 21 North American Cardiac Biomarker Market, by Biomarker Type, 2017 (\$ Millions)	128
Figure 22 North American Cardiac Biomarker Market Share, by Country, 2017 (%)	133
Figure 23 United States Cardiac Biomarker Market, by Biomarker Type, 2017 (\$ Millions)	135
Figure 24 European Cardiac Biomarker Market, by Biomarker Type, 2017 (\$ Millions)	138
Figure 25 European Cardiac Biomarker Market Share, by Country, 2017 (%).....	143
Figure 26 Asia-Pacific Cardiac Biomarker Market, by Biomarker, 2017 (\$ Millions)	153
Figure 27 Asia-Pacific Cardiac Biomarker Market Share, by Country, 2017 (%).....	160
Figure 28 Central and Latin American Cardiac Biomarker Market, by Biomarker Type, 2017 (\$ Millions)	166
Figure 29 Central and Latin American Cardiac Biomarker Market Share, by Country, 2017 (%)	173
Figure 30 Middle East and African Cardiac Biomarker Market, by Biomarker Type, 2017 (\$ Millions) ...	180
Figure 31 Middle East and African Cardiac Biomarker Market Share, by Region, 2017 (%).....	183
Figure 32 Private Health Insurance Coverage for U.S. Residents under 65, 2007–2011 (Millions/%)	200
Figure 33 Illustration of Medicare Payment Process.....	204
Figure 34 French Pricing and Reimbursement Process for Medical Devices.....	216
Figure 35 Market Access Pathway for Inpatient Medical Devices in Italy	219
Figure 36 Market Access Pathway for Outpatient Medical Devices in Italy	220
Figure 37 The Chinese Healthcare System.....	224



About BCC Research

About BCC Research

With our unparalleled 45-year history, BCC Research provides comprehensive analyses of global market sizing, forecasting and industry intelligence, covering markets where advances in science and technology are improving the quality, standard and sustainability of businesses, economies and lives.

BCC Library Access

From market sizing and forecasts, to opportunity assessments and competitive analyses, our ever-expanding library gives you the data, insights and intelligence required to ensure your project is a success. With myriad options for access to fit all needs and budgets, call 866/285-7215 or e-mail info@bccresearch.com to request a demo.

BCC Custom Research

Our experts provide custom research projects to those working to identify new markets, introduce new products, validate existing market share, analyze competition, and assess the potential for products to impact existing markets. With impressive academic credentials and broad and deep knowledge of global industrial markets, our independent analysts and consultants develop the facts, figures, analyses, and assessments to inform the decisions that will move your company ahead. Confidential inquiries to: custom@bccresearch.com or 781/205-2429.

DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and is of a professional nature. This information does not constitute managerial, legal or accounting advice, nor should it be considered as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is speculative in nature. BCC Research and the author assume no responsibility for any loss or damage that might result from reliance on the reported information or from its use.

ISBN: 978-1-62296-775-9
July 2018